{{Chembox
| Name = 
| ImageFile = Alisertib.svg
| IUPACName = 4-{[9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5''H''-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid
| SystematicName = 4-{[9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5''H''-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid
| OtherNames = 
|Section1={{Chembox Identifiers
| IUPHAR_ligand = 7790
| Abbreviations = 
| CASNo = 1028486-01-2
| EINECS = 
| PubChem = 24771867
| ChemSpiderID = 24700147
| SMILES = COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC
| InChI = 1/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)
| InChIKey = ZLHFILGSQDJULK-UHFFFAOYAB
| StdInChI = 1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)
| StdInChIKey = ZLHFILGSQDJULK-UHFFFAOYSA-N
| RTECS = 
| MeSHName = 
| ChEBI = 
| ChEMBL = 483158
| UNII = T66ES73M18
| KEGG = D10085
}}
|Section2={{Chembox Properties
| C=27 | H=20 | Cl=1 | F=1 | N=4 | O=4
| Appearance = 
| Density = 
| MeltingPt = 
| MeltingPt_notes = 
| BoilingPt = 
| BoilingPt_notes = 
| Solubility = 
| SolubleOther = 
| Solvent = 
| LogP = 
| VaporPressure = 
| HenryConstant = 
| AtmosphericOHRateConstant = 
| pKa = 
| pKb = 
  }}
|Section3={{Chembox Structure
| CrystalStruct = 
| Coordination = 
| MolShape = 
  }}
|Section4={{Chembox Thermochemistry
| DeltaHf = 
| DeltaHc = 
| Entropy = 
| HeatCapacity = 
  }}
|Section5={{Chembox Pharmacology
| AdminRoutes = 
| Bioavail = 
| Metabolism = 
| HalfLife = 
| ProteinBound =
| Excretion = 
| Legal_status = 
| Legal_US = 
| Legal_UK = 
| Legal_AU = 
| Legal_CA = 
| Pregnancy_category = 
| Pregnancy_AU = 
| Pregnancy_US = 
  }}
|Section6={{Chembox Explosive
| ShockSens = 
| FrictionSens = 
| DetonationV = 
| REFactor = 
  }}
|Section7={{Chembox Hazards
| ExternalSDS = 
| EUClass = 
| MainHazards = 
| NFPA-H = 
| NFPA-F = 
| NFPA-R = 
| NFPA-S = 
| RPhrases = 
| SPhrases = 
| RSPhrases = 
| FlashPt = 
| AutoignitionPt = 
| ExploLimits = 
| LD50 =
| PEL = 
  }}
|Section8={{Chembox Related
| OtherAnions = 
| OtherCations = 
| OtherFunction = 
| OtherFunction_label = 
| OtherCompounds = 
  }}
}}

'''Alisertib''' ('''MLN8237''') is an orally available selective [[aurora A kinase]] inhibitor developed by [[Takeda Pharmaceutical Company|Takeda]].<ref>{{cite journal|last=Friedberg|first=JW|last2=Mahadevan |first2=D |last3=Cebula |first3=E |last4=Persky |first4=D |last5=Lossos |first5=I |last6=Agarwal |first6=AB |last7=Jung |first7=J |last8=Burack |first8=R |last9=Zhou |first9=X |last10=Leonard |first10=EJ |last11=Fingert |first11=H |last12=Danaee |first12=H |last13=Bernstein |first13=SH|title=Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.|journal=Journal of Clinical Oncology|date=Jan 1, 2014|volume=32|issue=1|pages=44â€“50|pmid=24043741|doi=10.1200/JCO.2012.46.8793}}</ref>  It was investigated as a treatment for relapsed or refractory [[peripheral T-cell lymphoma]].<ref>{{cite web|title=Millennium Initiates Pivotal Phase 3 Trial of MLN8237 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma|url=http://www.takeda.com/news/2012/20120306_3946.html|publisher=Takeda Pharmaceutical Company Limited; Millennium Pharmaceuticals, Inc.|accessdate=20 March 2014|date=March 6, 2012}}</ref><ref>{{cite web|title=Research and Development Pipeline (As of February 5, 2014)|url=http://www.takeda.com/research/files/pipeline_20140205_en.pdf|publisher=Takeda Pharmaceutical Company Limited|accessdate=20 March 2014|page=2|date=February 5, 2014}}</ref> Development was abandoned in 2015 due to poor clinical trial results.<ref>https://www.takeda.com/newsroom/newsreleases/2015/takeda-announces-termination-of-alisertib-phase-3-trial-in-relapsed-or-refractory-peripheral-t-cell-lymphoma/</ref>

==References==
{{reflist}}

[[Category:Protein kinase inhibitors]]
[[Category:Benzoic acids]]
[[Category:Fluoroarenes]]
[[Category:Abandoned drugs]]
[[Category:Takeda Pharmaceutical Company]]
[[Category:Chloroarenes]]


{{organic-compound-stub}}